phrykt

Lipocine Inc. (LPCN): who owns it and who trades it

As of Nov 16, 2026, LPCN insiders reported 9 purchases worth $596K in the last 12 months. The largest buyer was John W. Higuchi (Director), with $416K. 2 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Lipocine

From the latest filings

Overall: more buying than selling. Insiders mostly bought. Famous investors was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Insider trades

In the last 12 months, LPCN insiders reported $596K of open-market purchases and $0 of sales.

Purchases, 12 months
$596K
9 trades, 2 people
Sales, 12 months
$0
0 trades, 0 people
Sales under a 10b5-1 plan
–
Share of sale value
Latest trade
Nov 13, 2026
Filed Nov 13, 2026

Purchases and sales by month

$435K$435KDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Nov 13, 2026Mahesh V. PatelCEOPurchase25,000$1.60$40KForm 4
Nov 12, 2026Mahesh V. PatelCEOPurchase25,000$1.58$39.5KForm 4
Sep 30, 2026John W. HiguchiDirectorPurchase15,970$2.23$35.6KForm 4
Sep 29, 2026John W. HiguchiDirectorPurchase9,037$2.15$19.4KForm 4
Sep 28, 2026John W. HiguchiDirectorPurchase12,561$2.16$27.1KForm 4
Apr 7, 2026John W. HiguchiDirectorPurchase40,000$2.03$81.2KForm 4
Apr 6, 2026John W. HiguchiDirectorPurchase123,000$2.05$252KForm 4
Apr 6, 2026Mahesh V. PatelCEOPurchase25,000$2.03$50.7KForm 4
Apr 2, 2026Mahesh V. PatelCEOPurchase25,000$2.02$50.5KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
John W. HiguchiDirector$416K–Sep 30, 2026
Mahesh V. PatelChief Executive Officer, Director$181K–Nov 13, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

LPCN short interest

Low short interest. 3.9% of LPCN shares are sold short: about 1 share in 25. Over the last 12 reports the number of shares short went up 219%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 325,401 LPCN shares were sold short, 3.9% of the shares outstanding, down 7.4% from the report before. At the average daily volume of 216,649 shares, buying them all back would take about 1.5 trading days (days to cover).

Shares short, % of all shares

3.95%May 15Oct 304.73%

Days to cover

1.5May 15Oct 305.1

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 2026325,4013.95%-7%216,6491.5
Oct 15, 2026351,4334.26%+259%9.62M1.0
Sep 30, 202697,8161.19%-2%43,2792.3
Sep 15, 202699,4441.21%-2%21,6904.6
Aug 31, 2026100,9921.22%+7%33,5323.0
Aug 14, 202694,4271.15%-15%50,3421.9
Jul 31, 2026110,9621.52%-10%31,1673.6
Jul 15, 2026123,0241.69%-13%41,2013.0
Jun 30, 2026141,7191.94%-7%86,4891.6
Jun 15, 2026152,3442.09%+69%125,4661.2
May 29, 202690,2381.24%-12%83,4891.1
May 15, 2026102,1331.40%-41%103,7621.0

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Lipocine company events

Lipocine filed 34 reports on Form 8-K in the last 12 months, 5 of them about an important change (leadership). The latest was on Nov 10, 2026.

  1. Nov 10, 2026AnnouncementThe Company issued a press release announcing the dosing of the first participant in its BLOOM Phase 3 Study of LPCN 1154 for postpartum depression. Filing
  2. Nov 5, 2026ResultsReleased financial results. Filing
  3. Oct 20, 2026AnnouncementThe Company has updated its corporate presentation that it uses when meeting with investors, analysts and others. Filing
  4. Oct 7, 2026AnnouncementThe Company announced that Health Canada had approved TLANDO ® for testosterone replacement therapy in adult males. Filing
  5. Sep 16, 2026AnnouncementThe Company presented at H.C. Wainwright 28 th Annual Global Investor Conference which was being held September 14 – 16, 2026, in New York City, NY. A copy of the presentation is furnished as Exhibit 99.1 to this report and incorporated by reference herein. Filing
  6. Sep 14, 2026AnnouncementThe Company issued a press release announcing the initiation of its BLOOM Phase 3 Study of LPCN 1154 for postpartum depression. Filing
  7. Sep 11, 2026AnnouncementLipocine Inc. and A.G.P./Alliance Global Partners agreed that the Sales Agent’s fee on sales made under that certain Sales Agreement dated April 26, 2024 between the Company and the Sales Agent will be up to 3.0%, subject to adjustment by the Company and the Sales Agent. Filing
  8. Sep 10, 2026AnnouncementThe Company issued a press release announcing that it is presenting and meeting with investors at the H.C. Wainwright 28 th Annual Global Investor Conference held September 14 – 16, 2026, in New York City, NY. A copy of the press release is furnished as Exhibit 99.1 to this report to this report… Filing
  9. Aug 21, 2026LeadershipAmended an earlier report. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Offices Appointment of Michael Grissinger to the Compensation Committee of the Board of Directors On August 18, 2026, the Board of Directors of the Company… Filing
  10. Aug 4, 2026ResultsReleased financial results. Filing
  11. Aug 3, 2026LeadershipDeparture of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Offices Appointment of Michael Grissinger as a Director On August 3, 2026, the Board of Directors of the Company expanded the Board of Directors to five members… Filing
  12. Jun 12, 2026AnnouncementThe Company hosted a virtual key opinion leader event highlighting the unmet needs in postpartum depression and the clinical profile of LPCN 1154. Filing
  13. Jun 4, 2026LeadershipDeparture of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers As noted below, on June 3, 2026, the shareholders of Lipocine Inc. approved the Sixth Amended and Restated 2014 Stock and Incentive Plan. Filing
  14. Jun 4, 2026AnnouncementThe Company issued a press release announcing Lipocine will be hosting a virtual KOL event highlighting unmet needs in postpartum depression and the clinical profile of LPCN 1154 on Friday, June 12, 2026, at 11:00 AM Eastern Time. Filing
  15. May 26, 2026AnnouncementThe Company presented its Phase 3 clinical data for LPCN 1154 and a poster at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting held May 26 th through the 29 th, 2026 in Miami Beach, FL. The presentation highlighted the results from Lipocine’s Phase 3 placebo-controlled… Filing
  16. May 19, 2026AnnouncementThe Company issued a press release announcing Lipocine’s LPCN 1154 Phase 3 data has been accepted for oral presentation at the 2026 ASCP Annual Meeting to be held May 26-29, 2026, in Miami, Florida. Filing
  17. May 18, 2026AnnouncementThe Company issued a press release announcing Lipocine to present at A.G.P.’s Annual Virtual Healthcare Company Showcase on Wednesday, May 20, 2026. Filing
  18. May 7, 2026AnnouncementThe Company has updated its corporate presentation that it uses when meeting with investors, analysts and others. Filing
  19. May 7, 2026ResultsReleased financial results. Filing
  20. Apr 21, 2026LeadershipSpyros Papapetropoulos informed the Board of Directors of Lipocine Inc. that he resigned as a member of the Board effective immediately. Filing
  21. Apr 2, 2026AnnouncementThe Company has updated its corporate presentation that it uses when meeting with investors, analysts and others. Filing
  22. Apr 2, 2026AnnouncementThe Company issued a press release announcing topline safety and efficacy results for LPCN 1154 in patients with postpartum depression. Filing
  23. Mar 10, 2026ResultsReleased financial results. Filing
  24. Mar 4, 2026AnnouncementLipocine Inc. entered into a sales agreement with A.G.P./Alliance Global Partners as sales agent to offer and sell shares of its common stock, par value $0.0001 per share, from time to time through the Sales Agent. Filing
  25. Feb 18, 2026AnnouncementThe Company has updated its corporate presentation that it uses when meeting with investors, analysts and others. Filing
  26. Feb 18, 2026AnnouncementThe information contained above in Item 2.02 is hereby incorporated by reference into this Item 8.01. Filing
  27. Jan 20, 2026AnnouncementThe Company issued a press release announcing completion of enrollment and dosing in Phase 3 Trial of LPCN 1154 in postpartum depression. Filing
  28. Jan 12, 2026AnnouncementThe Company has updated its corporate presentation that it uses when meeting with investors, analysts and others. Filing
  29. Jan 12, 2026AnnouncementThe Company issued a press release reporting encouraging progress post second interim safety review in Phase 3 Trial of LPCN 1154 in postpartum depression. Filing
  30. Dec 16, 2025AnnouncementThe Company issued a press release announcing Lipocine’s PPD Phase 3 Study (LPCN 1154) had hit 80% enrollment. Filing
  31. Dec 15, 2025LeadershipJeffrey Fink informed the Board of Directors of Lipocine Inc. that he will resign from the Board effective January 1, 2026 for personal reasons. Filing
  32. Dec 11, 2025AnnouncementThe Company presented posters for LPCN 2101 at the American Epilepsy Society (AES) Annual Meeting held December 5 th through the 9 th, 2025 in Atlanta, GA. The posters are furnished as Exhibit 99.1 and 99.2 to this report and incorporated by reference herein. Filing
  33. Nov 18, 2025AnnouncementThe Company has updated its corporate presentation that it uses when meeting with investors, analysts and others. Filing
  34. Nov 18, 2025AnnouncementThe Company issued a press release highlighting the promising interim safety profile of LPCN 1154 in our Phase 3 clinical trial in postpartum depression (PPD). Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Lipocine financials

Famous investors that hold LPCN

2 of the 50 well-known investors we track reported holding LPCN in their latest 13F filing. The largest position is Ken Griffin's, worth $171K.

FundQuarterSharesValueOf portfolioChange
Ken Griffin · Citadel AdvisorsQ3 202677,677$171K0.0%-4%
Jim Simons · Renaissance TechnologiesQ3 202670,284$155K0.0%+2%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

Questions about Lipocine Inc. (LPCN) stock

Are LPCN insiders buying or selling?

In the last 12 months, LPCN insiders reported 9 open-market purchases worth $596K and no sales. The latest trade was on Nov 13, 2026. See every trade.

What is the short interest in LPCN?

As of Oct 30, 2026, 325,401 LPCN shares were sold short, 3.9% of the shares outstanding, down 7.4% from the report before. At the average daily volume of 216,649 shares, buying them all back would take about 1.5 trading days (days to cover). See the history.

Which famous investors hold LPCN?

2 of the 50 well-known investors we track reported LPCN in their latest 13F filing, including Ken Griffin, Jim Simons. The largest position is worth $171K. See all holders.

Executive pay

Lipocine's chief executive was paid a total of $986K for the year ended Dec 31, 2025, up 29% from $762K the year before. In the last 12 months, Lipocine's executives and directors bought $596K of stock on the open market and sold none.

Chief executive, total pay$986KYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$1.1MThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$488KThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.